GALACELAGALARISSO
SLEDM
By exploring new frontiers in science and technology, we strive to accelerate innovation of transformational medicines that deliver more years of life and quality of life for patients and families living with immune-mediated conditions.
We announced a planned separation into two entities: Galapagos, and a newly to be formed company (“SpinCo”).
We are exploring partnering opportunities to advance our potential best-in-class small molecule programs.
This includes the TYK2 inhibitor, GLPG3667, currently in Phase 2 development for systemic lupus erythematosus, dermatomyositis, and other potential autoimmune indications.
GALACELAGALARISSO
SLEDM
pBIC: potential Best-In-Class; SLE: Systemic lupus erythematosus; DM: Dermatomyositis
Experienced and purpose-driven
With over 20 years of research under our belt, we have built a vast proprietary knowledge of disease biology.
By exploring new frontiers in science and technology, we strive to accelerate innovation of transformational medicines that deliver more years of life and quality of life for patients and families living with immune-mediated conditions.
Pioneering for patients
affected by immune-mediated diseases1
of immune-mediated diseases
mistakenly attacks healthy cells and tissues
1 World Health Organization. (2020). Global Report on Immune-Mediated Diseases. https://www.who.int/publications/i/item/global-report-on-immune-mediated-diseases)
Our focus in immunology
All about Galapagos
Everything you need to know about Galapagos in one slide deck.
Disease areas
We are united around our mission to redefine the future of cancer treatment. Our goal is to help people facing cancer live longer, better lives.
Partnerships
We are adding new capabilities, technologies and product candidates through internal and external innovation. Let’s start #PioneeringForPatients, together!